Challenges in Parkinson’s Disease Diagnosis in a Patient with Ipsilateral Hemimelia
Objective: Our main objective is to demonstrate the challenges involved in the diagnosis of parkinsonism in a patient with transverse failure of formation of the…Freezing of Gait in Parkinson’s Disease: Risk Factors and Associated Nonmotor Symptoms
Objective: To clarify risk factors for, and clinical associations of, freezing of gait (FOG) in Parkinson's disease (PD). Background: FOG is a disabling and incompletely…Moaning: genetic analysis of a family with eight affected members
Objective: To report the clinical and genetic evaluation of a five-generation family with eight members exhibiting moaning. Background: Moaning is characterized by low-tone abnormal involuntary,…Gene Expression Profiling of depression in Huntington’s disease
Objective: This preliminary study was designed to investigate the gene expression profile by RNA-seq in HD patients with depression and without depression, and between subjects…Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease
Objective: The present study examined the potential neuroprotective and neurotrophic efficacy of GBE against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD…Huntington’s Disease Protein Huntingtin Associates with its own mRNA
Objective: To investigate how Htt might affect RNA metabolism we set out to purify and analyze RNA associated with Htt. Background: The Huntington's disease (HD)…Assessment of Caregiver Burden in Huntington’s disease
Objective: We aim to identify and characterize caregiver burden among HD caregivers, to see what aspects of HD caregiving are associated with the greatest burden…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program
Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 217
- Next Page »